Who Paid My Doc
Robert Weisman
Forensic Psychiatry Rochester, NY Doctor of Osteopathy
NPI 1710914965 CMS profile 1152560
601 Elmwood Ave, Rochester, NY 14642
General payments
$20
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Robert Weisman of Rochester, NY is reported in the CMS Open Payments database as having received $20 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 7th percentile of Forensic Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $20 | 1 |
Beside peers
- Robert Weisman
- Forensic Psychiatry median
- Middle half of Forensic Psychiatry
- National median
In program year 2025, general payments to Robert Weisman were reported at $20. Among 86 Forensic Psychiatry profiles paid that year, the median was $125 and the middle half received between $34 and $306.
Show as a table
| Year | Robert Weisman | Forensic Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $143 | $61–$431 | $163 |
| 2020 | $0 | $112 | $36–$301 | $114 |
| 2021 | $0 | $113 | $38–$343 | $132 |
| 2022 | $0 | $113 | $67–$475 | $149 |
| 2023 | $0 | $139 | $66–$415 | $160 |
| 2024 | $0 | $117 | $36–$341 | $164 |
| 2025 | $20 | $125 | $34–$306 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
109
Drug cost
$2,323
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Haloperidol Decanoate | Generic | 16 | $1,286 | |
| Aripiprazole | Generic | 12 | $441 | |
| Olanzapine | Generic | 30 | $218 | |
| Hydroxyzine Hcl | Generic | 11 | $155 | |
| Haloperidol | Generic | 11 | $115 | |
| Benztropine Mesylate | Generic | 17 | $75 | |
| Trazodone Hcl | Generic | 12 | $34 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Forensic Psychiatry in New York
Jason Hershberger
Forensic Psychiatry · Brooklyn, NY
Martin Drooker
Forensic Psychiatry · New York, NY
Patrick Rowan
Forensic Psychiatry · Brooklyn, NY
Tina Krishnarao
Forensic Psychiatry · New York, NY
Joel Idowu
Forensic Psychiatry · Staten Island, NY
Richard Wang
Forensic Psychiatry · New Hampton, NY
Related records
Forensic Psychiatry in New York
Practitioners in the same specialty and state, ranked by reported value.
All Forensic Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.